Longeveron Secures FDA Meeting Ahead of Key HLHS Trial Data
Event summary
- Longeveron has secured a Type C meeting with the FDA to discuss clinical endpoints and statistical analysis for its Phase 2 ELPIS II trial.
- The ELPIS II trial is evaluating laromestrocel (LOMECEL-B®) as an adjunct therapy for Hypoplastic Left Heart Syndrome (HLHS).
- Top-line data from ELPIS II is expected in Q3 2026, with a potential Biologics License Application (BLA) submission if results are positive.
- The trial enrolled 40 pediatric patients across 12 institutions and is being conducted in collaboration with NHLBI and NIH.
The big picture
Longeveron's HLHS program represents a significant opportunity within the rare disease space, which is increasingly attracting investment due to unmet medical needs and regulatory incentives. The FDA’s designations highlight the potential for laromestrocel to address a critical gap in treatment for HLHS, a condition with a high mortality rate despite surgical interventions. However, the success of the ELPIS II trial and subsequent regulatory approval remain key risks.
What we're watching
- Regulatory Risk
- The outcome of the Type C meeting will be crucial, as FDA alignment on endpoints directly impacts the likelihood of BLA approval and the potential for accelerated pathways.
- Clinical Efficacy
- The ELPIS II trial's success hinges on demonstrating a meaningful improvement in right ventricular function, given the high mortality rate (50%) even with current surgical interventions.
- Commercialization
- While HLHS is rare, the Orphan Drug and Fast Track designations suggest a potentially lucrative market; Longeveron’s ability to scale production and distribution will be critical if the therapy proves effective.
Related topics